Abstract #2722

Breast Tumor Metabolic Imaging Biomarker kio Correlates with Histopathology Residual Cancer Measures

Charles S. Springer, Jr.^1,2, Xin Li¹, Alina Tudorica³, Karen Y. Oh³, Stephen Y-C. Chui^2,4, Nicole Roy³, Megan L. Troxell^2,5, Arpana Naik^2,6, Kathleen A. Kemmer⁴, Yiyi Chen^2,7, Megan L. Holtorf², Aneela Afzal¹, and Wei Huang^1,2

¹Advanced Imaging Research Center, Oregon Health & Science University, Portland, OR, United States, ²Knight Cancer Institute, Oregon Health & Science University, Portland, OR, United States, ³Diagnostic Radiology, Oregon Health & Science University, Portland, OR, United States, ⁴Medical Oncology, Oregon Health & Science University, Portland, OR, United States, ⁵Pathology, Oregon Health & Science University, Portland, OR, United States, ⁶Surgical Oncology, Oregon Health & Science University, Portland, OR, United States, ⁷Public Health and Preventive Medicine, Oregon Health & Science University, Portland, OR, United States

The new DCE-MRI biomarker k_io measures on-going vital metabolic activity. Whole breast tumor k_io correlates well with pathology determinations of residual cancer burden and tumor invasive cell volume fraction from surgical specimens obtained just a few days later.

This abstract and the presentation materials are available to members only; a login is required.

Join Here